Navigation Links
UC Davis researchers discover a key to aggressive breast cancer
Date:10/30/2008

(SACRAMENTO, Calif.) In trying to find out why HER2-positive breast cancer can be more aggressive than other forms of the disease, UC Davis Cancer Center researchers have surprisingly discovered that HER2 itself is the culprit. By shutting down its own regulator gene, HER2 creates a permissive environment for tumor growth.

Building on recent research showing that the regulator labeled LRIG1 and commonly called "Lig-1" limits the growth-promoting signals of HER2, the research team set out to clarify the role of Lig-1 in breast cancer.

They found that, when compared to healthy breast tissue, the regulator is significantly suppressed.

"This suppression assists HER2 in its own over-expression and in driving the growth of cancer cells," said Colleen Sweeney, associate professor of biochemistry and molecular medicine and senior author of the study, which appears in this month's issue of Cancer Research. "HER2 is clearly taking an active role its own ability to be successful in promoting cancer."

Sweeney added that the study results could lead to new treatments aimed at restoring or replacing functions of the regulator. This is good news for patients because, in addition to being more aggressive, HER2-positive breast cancer tends to be less responsive to currently available treatments. The gene is over-expressed in about one-quarter to one-third of breast cancer cases.

Sweeney and colleagues began by studying mouse models of breast cancer with genomes that carry extra copies of HER2. They noticed an excess of HER2 protein in the resulting tumors, but it was not over-expressed in adjacent healthy tissues that also carried extra copies of the HER2 gene.

"That suggested to us that extra copies of HER2 alone are not enough to explain its over-expression. If it was, HER2 would have been over-expressed in both normal and tumor tissues from these mice," she said.

Given that observation, the team set out
'/>"/>

Contact: Karen Finney
karen.finney@ucdmc.ucdavis.edu
916-734-9064
University of California - Davis - Health System
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UC Davis chemical ecologist wins major award
2. UC Davis researchers discover new drug target for inflammatory disease
3. UC Davis researchers define characteristics, treatment options for XXYY syndrome
4. UC Davis researcher leads climate-change discovery
5. UC Davis stem researchers demonstrate safety of gene therapy using adult stem cells
6. UC Davis researchers discover how HIV turns food-poisoning into lethal infection
7. UC Davis bird-flu expert calls for changes in early-warning system
8. Caltech-led researchers find negative cues from appearance alone matter for real elections
9. ASU researchers receive NIH awards for studies of malaria and emergent disease
10. Stanford researchers: Global warming is killing frogs and salamanders in Yellowstone Park
11. Syracuse University researchers discover new way to attack some forms of leukemia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2009)...rstCall/ -- BIO-key International, Inc. (OTC Bulle...ic identification software is showcasing donor and...rence being held at the New Orleans Convention Cen...hands-on product demonstrations of its state-of-th...o, at 5 PM on Monday, October 26, Peter Lux, manag...
(Date:11/4/2009)...encoe Software, Inc., the commercial arm of the Op...://openmicroscopy.org ), is proud to announce its...iology,s exciting new project titled "The Cell: An... stimulus grant through the National Institutes of...rt of the American Reinvestment and Recovery Act, ...
(Date:11/3/2009)...published in a recent issue of HortTechnology , s...the effects of covering orchard floors with reflec...ight distribution, orchard temperature, and profit...nday and Solarmate films installed 5 weeks before ...pples. The research showed that the use of both fi...
Breaking Biology News(10 mins):BIO-key(R) International Exhibiting at AABB TXPO 2Glencoe Software to Support the ASCB 'Stimulus Grant' to Build Virtual Image Library of the Cell 2Reflective film can boost profits for apple growers 2China Medical Technologies Announces the Substantial Completion of an Independent Internal Investigation and Expected Timing of Reporting of Unaudited 53242 1China Medical Technologies Announces the Substantial Completion of an Independent Internal Investigation and Expected Timing of Reporting of Unaudited 53242 2China Medical Technologies Announces the Substantial Completion of an Independent Internal Investigation and Expected Timing of Reporting of Unaudited 53242 3China Medical Technologies Announces the Substantial Completion of an Independent Internal Investigation and Expected Timing of Reporting of Unaudited 53242 4Learning Takes Place When You Get Things Right 53240 1Learning Takes Place When You Get Things Right 53240 2The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 1The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 2
...anes, submarines and even automobiles of tomorrow ...rformance micro-mechanical gyroscopes for navigati...EMS gyroscope arrays being developed by a team con...avrik of Oak Ridge National Laboratory is radicall... and costly. Instead, this system consists of mult...
...this summer where the tiger,s roar will meet birds...ll be heard next door to advanced sonar systems; w... the smashing falls of Antarctic ice shelves. , ...d to them -- will only be found at the Acoustics,0... Friday July 4, 2008 at the Palais des Congrs in P...
...r Medical Research, led by Jos Luis Milln, Ph.D., ... of enzyme replacement therapy to prevent hypophos...tic origin. This discovery lays the foundation fo...ckets is a softening of the bones that most common... from insufficient exposure to sunlight. Hypophosp...
Other Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2008 3Potential therapy discovered for hypophosphatasia, a congenital form of rickets 2
(Date:11/5/2009)...Nov. 5 Cepheid (Nasdaq: ...e speaking at the following investor conferences, ..., , Credit Suisse Healthcare Confe...ovember, 2009 at 10 a.m. Mountain Time, ...ngland, Tuesday, 1 December, 2009 ...
(Date:11/5/2009)...mber 5, 2009 Senomyx, In...oprietary taste receptor-based technologies to dis...age, and ingredient supply industries, today provi...lts for the third quarter ended September 30, 2009...r of 2009, compared to $4.0 million for the third ...
(Date:11/5/2009)... 5 SpineSmith Partners has signed ...elop a unique scaffold that mimics the structure o...f several commercial products by SpineSmith,s Rese...ves the GenOsteo scaffold represents a significant...nd ideal environment for the delivery of adult ste...
(Date:11/5/2009)... Drug safety specialty firm BioSoteria announced t...s earned the Certified Professional in Learning an...erican Society for Training and Development (ASTD)...re than fifteen years of medical communications an...le for the development of the company,s online pha...
Breaking Biology Technology:Cepheid to Webcast Upcoming Financial Presentations 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 2BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 3BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 4
...chnologies,Corporation, a leader in tumor-targeted...l European patents for the platform targeting tech...on gene delivery to primary cancers and,metastatic...h profound,demonstrations of clinical benefit and ...Epeius Biotech continues to lead the field of clin...
...siva,Inc. (Nasdaq: ANSV ) today announced top-li...ng Adlea(TM), its long-acting, non-opioid analgesi...dpoint of reducing post-surgical,pain versus place..., or total,knee replacement surgery) at four to 48...econdary endpoint with Adlea demonstrating a highl...
...alize Colorectal Cancer Treatment Determining Who ...KS, Calif., Dec. 16 Amgen (Nasdaq: AMGN ) today ...f the KRAS gene as a predictive biomarker in pat...ated with anti-epidermal growth factor receptor (E....S. Food and Drug Administration,s (FDA) Oncologic...
Other Biology Technology:Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate 2Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 2Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 3Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 4Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 2Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 3Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 4Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 5Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 6Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 7Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 8
...cally collected via cardiac puncture from 3 to 4 w... is then centrifuged and frozen at -70C. The compl...led at 4C then stored at -70C. DIRECT SALES FROM P...FREEZ COMPLEMENT, YOU CAN NOW BUY DIRECTLY FROM TH...
Thermal Grayscale USB Printer for Imaging Systems; USB Connection from Alpha Innotech
GIBCO Newborn Calf Serum Heat-Inactivated from Invitrogen
Ready-To-Use IHC Bluing Reagent from Bethyl Laboratories
Biology Products: